Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, Markus HS, Bath MW, Bath PM; Acute Antiplatelet Stroke Trialists Collaboration. Geeganage CM, et al. Among authors: topol ej. Stroke. 2012 Apr;43(4):1058-66. doi: 10.1161/STROKEAHA.111.637686. Epub 2012 Jan 26. Stroke. 2012. PMID: 22282894 Review.
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
Aronow HD, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, Fitzgerald DJ, Easton JD, Van de Werf F, Diener HC, Ferguson J, Koudstaal PJ, Amarenco P, Theroux P, Davis S, Topol EJ. Aronow HD, et al. Among authors: topol ej. Am J Cardiol. 2008 Nov 15;102(10):1285-90. doi: 10.1016/j.amjcard.2008.07.019. Epub 2008 Sep 15. Am J Cardiol. 2008. PMID: 18993142
Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.
Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, Bhatt DL, Fox KA, Topol EJ; CHARISMA Trial Investigators. Hankey GJ, et al. Among authors: topol ej. Stroke. 2010 Aug;41(8):1679-83. doi: 10.1161/STROKEAHA.110.586727. Epub 2010 Jul 1. Stroke. 2010. PMID: 20595658 Clinical Trial.
Statin use and sex-specific stroke outcomes in patients with vascular disease.
Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Bushnell CD, et al. Among authors: topol ej. Stroke. 2006 Jun;37(6):1427-31. doi: 10.1161/01.STR.0000221315.60282.ca. Epub 2006 Apr 27. Stroke. 2006. PMID: 16645137
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators. Wang TH, et al. Among authors: topol ej. Eur Heart J. 2007 Sep;28(18):2200-7. doi: 10.1093/eurheartj/ehm274. Epub 2007 Aug 2. Eur Heart J. 2007. PMID: 17673448 Clinical Trial.
1,220 results